文献速递认知障碍与痴呆

常染色体显性阿尔茨海默病家系个体神经影像学生物标志物变化的空间模式:纵向研究

Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study.
PubMed 文献 · Lancet Neurol · 2018-02-01

研究分析了来自常染色体显性阿尔茨海默病家系的突变非携带者、无症状携带者和症状性携带者的11C-PiB PET、18F-FDG PET和结构MRI数据,发现突变携带者中Aβ沉积速率最先出现异常,随后为代谢减低,最后为结构萎缩,且各生物标志物在脑内出现时间因区域而异。

要点

  • 突变携带者Aβ沉积速率最先与不携带者出现显著差异,平均在预期发病前18.9年。
  • 代谢减低平均在预期发病前14.1年出现,结构萎缩平均在预期发病前4.7年出现。
  • 楔前叶是每种方法中最早出现组间差异的皮层区域。

核心结论

  • 突变携带者较非携带者出现Aβ沉积升高、葡萄糖代谢减低和皮层变薄,且这些变化早于预期痴呆发病。

研究设计与样本

  • 研究于2009年1月1日至2015年12月31日纳入常染色体显性阿尔茨海默病家系(PSEN1、PSEN2或APP突变)的突变非携带者、无症状携带者和症状性携带者,分析11C-PiB PET、18F-FDG PET和结构MRI数据。
  • 11C-PiB PET可用346人(其中162人有纵向影像),18F-FDG PET可用352人(其中175人有纵向影像),MRI数据可用377人(其中201人有纵向影像)。
  • 使用线性混合效应模型估计基线时距症状发作估计年数对应的生物标志物变化率,并确定突变携带者与非携带者轨迹最早出现差异的时间点。

主要发现

  • Aβ沉积速率在突变携带者与非携带者间最先出现显著差异,在出现显著差异的脑区中平均于预期发病前18.9年(SD 3.3)。
  • 代谢减低平均于预期发病前14.1年(SD 5.1)出现,结构萎缩平均于预期发病前4.7年(SD 4.2)出现。
  • 楔前叶是每种方法中最早出现组间差异的皮层区域:Aβ积累于预期发病前22.2年,代谢减低于预期发病前18.8年,皮层变薄于预期发病前13.0年。
  • 生物标志物顺序在大多数但非全部脑区中保持不变,同一生物标志物在脑内出现时间因区域而异。

临床怎么用

  • 作者认为,应用生物标志物于临床以及设计和评估临床试验时,应考虑Aβ、代谢下降和结构萎缩在区域和时间上的不同易感性。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Models of Alzheimer's disease propose a sequence of amyloid β (Aβ) accumulation, hypometabolism, and structural decline that precedes the onset of clinical dementia. These pathological features evolve both temporally and spatially in the brain. In this study, we aimed to characterise where in the brain and when in the course of the disease neuroimaging biomarkers become abnormal. METHODS: Between Jan 1, 2009, and Dec 31, 2015, we analysed data from mutation non-carriers, asymptomatic carriers, and symptomatic carriers from families carrying gene mutations in presenilin 1 (PSEN1), presenilin 2 (PSEN2), or amyloid precursor protein (APP) enrolled in the Dominantly Inherited Alzheimer's Network. We analysed 11C-Pittsburgh Compound B (11C-PiB) PET, 18F-Fluorodeoxyglucose (18F-FDG) PET, and structural MRI data using regions of interest to assess change throughout the brain. We estimated rates of biomarker change as a function of estimated years to symptom onset at baseline using linear mixed-effects models and determined the earliest point at which biomarker trajectories differed between mutation carriers and non-carriers. This study is registered at ClinicalTrials.gov (number NCT00869817) FINDINGS: 11C-PiB PET was available for 346 individuals (162 with longitudinal imaging), 18F-FDG PET was available for 352 individuals (175 with longitudinal imaging), and MRI data were available for 377 individuals (201 with longitudinal imaging). We found a sequence to pathological changes, with rates of Aβ deposition in mutation carriers being significantly different from those in non-carriers first (across regions that showed a significant difference, at a mean of 18·9 years [SD 3·3] before expected onset), followed by hypometabolism (14·1 years [5·1] before expected onset), and lastly structural decline (4·7 years [4·2] before expected onset). This biomarker ordering was preserved in most, but not all, regions. The temporal emergence within a biomarker varied across the brain, with the precuneus being the first cortical region for each method to show divergence between groups (22·2 years before expected onset for Aβ accumulation, 18·8 years before expected onset for hypometabolism, and 13·0 years before expected onset for cortical thinning). INTERPRETATION: Mutation carriers had elevations in Aβ deposition, reduced glucose metabolism, and cortical thinning compared with non-carriers which preceded the expected onset of dementia. Accrual of these pathologies varied throughout the brain, suggesting differential regional and temporal vulnerabilities to Aβ, metabolic decline, and structural atrophy, which should be taken into account when using biomarkers in a clinical setting as well as designing and evaluating clinical trials. FUNDING: US National Institutes of Health, the German Center for Neurodegenerative Diseases, and the Medical Research Council Dementias Platform UK.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Gordon BA, Blazey TM, Su Y, et al. Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study. Lancet Neurol. 2018. PMID: 29397305. doi:10.1016/S1474-4422(18)30028-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。